Navigation Links
Cethromycin Shown Effective Against Anthrax in Study

Advanced Life Sciences Achieves Key Endpoint in Primate Study

CHICAGO, May 02, 2007 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. today announced that its novel respiratory antibiotic, Cethromycin, was shown to be effective in preventing inhalation anthrax infection. This conclusion was reached from a primate study where a 30-day course of oral Cethromycin was 100% protective against a lethal dose of inhaled anthrax as compared to the standard of care, Cipro(R) (ciprofloxacin), which demonstrated 90% protection.

"We felt confident going into the primate study because of Cethromycin's potent activity against over 30 strains of anthrax, yet the results have exceeded our expectations," said Dr. Michael T. Flavin, Chief Executive Officer for Advanced Life Sciences. "We believe that Cethromycin's unique antibacterial properties differentiate it from other antibiotics and, if approved by the FDA, may allow it to become a useful tool in the treatment of infections such as anthrax."

Cethromycin was recently granted Orphan Drug designation by the FDA for the prophylactic treatment of inhalation anthrax and is being developed in collaboration with U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and the NIH's National Institute of Allergy and Infectious Disease (NIAID). Cethromycin, which has been tested in over 4,400 human subjects, is also in pivotal Phase III trials for the treatment of community acquired pneumonia (CAP). The Company expects to report data from the CAP program in June of this year.

"With emerging bacterial resistance, both natural and engineered, there is a critical need for new antibiotics that work differently than currently available therapies to protect against anthrax," continued Dr. Flavin. "To our knowledge, there are no other antibiotics in late-stage development to address this need. Based on the human safety and animal efficacy dat a collected to date, we believe that Cethromycin could address this need and be considered for purchase by the U.S. Government under Project BioShield and the Strategic National Stockpile to provide protection to the American public in the event of an anthrax attack."

Primate Study Findings

In the study, 30 naive non-human primates were randomized into 3 groups of 10 animals and were aerosol challenged with Ames strain anthrax spores at a target dose of 50 LD50. Beginning 24 hours post-challenge, 10 primates were treated with 16 mg/kg (the human equivalent of 300 mg) Cethromycin once daily, 10 primates were treated with 16 mg/kg ciprofloxacin twice daily, and 10 primates received water for injection (2 ml/kg) once daily. All antibiotic treatments were by oral gavage for 30 days.

The study results showed that all ten Cethromycin-treated animals survived, with one of the ten demonstrating abnormal hematologic parameters following antibiotic cessation, which were then normalized. One of the ten ciprofloxacin-treated animals died nine days following cessation of ciprofloxacin treatments after demonstrating clinical signs of infection, bacteremia and alterations in hematologic and coagulation parameters. All ten control primates demonstrated a combination of clinical signs of anthrax, bacteremia, and alterations in hematologic and coagulation parameters post-challenge with five of ten succumbing to the infection.

FDA's "Animal Efficacy Rule" and the Use of Primates

Advanced Life Sciences is developing Cethromycin for the prophylactic treatment of inhalation anthrax to ultimately help protect against human infection from anthrax. The primates used in the study referenced above were used to help understand anthrax disease mechanisms and to assess novel ways to treat anthrax in lieu of human efficacy testing pursuant to FDA's "Animal Efficacy Rule" (21 C.F.R. Section 314.600-650). The study referenced above was carried out in accordance wi th the Animal Welfare Act (AWA) under the supervision of an Institutional Animal Care and Use Committee (IACUC), which is responsible for enforcing the AWA.

The "Animal Efficacy Rule" allows for approval of new drug products based on animal data when adequate and well-controlled efficacy studies in humans cannot be ethically conducted because the studies would involve administering a potentially lethal or permanently disabling toxic substance or organism to healthy human volunteers, and field trials are not feasible before approval. Approval of a drug under the "Animal Efficacy Rule" is subject to certain postapproval commitments, including the submission of a plan for conducting postmarketing studies, postmarketing restrictions to ensure safe use (if deemed necessary), and product labeling information intended for the patient advising that, among other things, the product's approval was based on effectiveness studies conducted in animals alone.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. For more information, please visit us on the web at

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependenc e on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

CONTACT: Media, Loretta Lepore, +1-404-527-4175; or Investor Relations,Janet Dally, +1-609-466-0466, both for Advanced Life Sciences Holdings,Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:ADLS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
2. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
3. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
6. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
7. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
8. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
9. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
10. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
11. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into its ... 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
Breaking Medicine News(10 mins):